Plaquenil for Alopecia Areata, Alopecia Totalis

Status Completed

Clinical Trial Summary

Alopecia areata is an autoimmune condition resulting in hair loss and complete baldness (alopecia totalis). Published evidence says that it is mediated by T-lymphocytes. Plaquenil is an anti-inflammatory drug approved by the FDA for malaria, lupus erythematosus, and rheumatoid arthritis. It has an effect on T-lymphocyte mediated inflammation, making it a logical choice for a treatment trail for alopecia areata.

Clinical Trial Description

Alopecia areata is a high prevalence autoimmune disease with significant consequences. Alopecia areata is a tissue restricted autoimmune disease directed at the hair follicle, resulting in hair loss. Patients frequently suffer severe psychiatric consequences. This is especially true of girls and young women who become bald. The incidence of alopecia areata in the USA (Minnesota is 20.2 per 100,000 person-years with a lifetime risk of approximately 1.7%. There is no significant gender difference. The disease is often chronic with a remitting, relapsing course. Although it responds to immunosuppression, generalized immunosuppression has significant morbidity and treatment is frequently frustrating and not successful. New treatment options are essential. With evidence that alopecia areata is a T-lymphocyte mediated autoimmune condition it has become a model system for the study of pathogenesis and treatment of T-cell mediated autoimmunity and as such is a model for a host of additional T-cell mediated autoimmune conditions. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00176982
Study type	Interventional
Source	University of Minnesota - Clinical and Translational Science Institute
Contact
Status	Completed
Phase	Phase 4
Start date	April 2002
Completion date	January 2008

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05051761` - Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata	Phase 3
Active, not recruiting	`NCT03570749` - A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata	Phase 2/Phase 3
Completed	`NCT02812342` - Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants	Phase 2
Completed	`NCT02350023` - Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata	Phase 4
Completed	`NCT02018042` - An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata	Phase 2
Terminated	`NCT01898806` - Intralesional Steroids in the Treatment of Alopecia Areata	Phase 4
Recruiting	`NCT04011748` - Clinical Application of Stem Cell Educator Therapy in Alopecia Areata	Phase 2
Terminated	`NCT04517864` - PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA	Phase 2
Not yet recruiting	`NCT05803070` - Topical Cetirizine in Treatment of Localized Alopecia Areata
Not yet recruiting	`NCT05496426` - A Study of KL130008 in Adults With Severe Alopecia Areata	Phase 2
Completed	`NCT04147845` - Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata	N/A
Terminated	`NCT03325296` - Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.	Phase 2
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Enrolling by invitation	`NCT05745389` - CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2
Not yet recruiting	`NCT06087796` - Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.	Phase 1
Withdrawn	`NCT03532958` - Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata	Phase 2
Recruiting	`NCT02604888` - Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females	N/A
Terminated	`NCT01385839` - Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata	N/A
Completed	`NCT00408798` - Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin	N/A